Given orally, testosterone is inactivated in the liver, so parenteral forms of administration or modifications of the molecule had to be found.[1] That single constraint, recognised almost immediately after 1935, is the reason testosterone products look the way they do today.
Everything since — the injectable esters, the implants, the patches, the gels, the sprays — is an answer to it.
What "inactivated in the liver" means
Anything absorbed from the gut goes to the liver before it reaches general circulation. For most drugs some fraction survives. For testosterone, the liver metabolises it so efficiently that an oral dose largely does not arrive.
Two escape routes exist, and both were pursued:
Bypass the gut. Deliver by a route that does not drain to the liver first — injection, or absorption through skin.
Change the molecule. Modify testosterone so it survives first-pass metabolism. This works chemically, but 17-alpha-alkylated oral androgens developed on this principle carry hepatic toxicity, which is why they are not the basis of modern replacement therapy.
Eighty-five years of "slowly"
The historical verdict is unsentimental: over 85 years, testosterone preparations have been slowly improved, so that physiological serum levels can now be achieved.[1]
The word doing the work there is slowly. This was not a solved problem in 1940, or 1970. Achieving physiological levels — not too high, not collapsing between doses — is a recent accomplishment, and the emphasis on physiological is deliberate: the goal of a modern regimen is the mid-normal range, not the highest attainable number.[2]
Why the ester was the first answer
The dominant early solution was esterification — attaching a fatty acid chain to the testosterone molecule and suspending it in oil for intramuscular injection. The ester slows release from the injection site, so one injection lasts days or weeks instead of hours.
That bought duration at the cost of a new problem: concentration that is high after the injection and low before the next one. The dose-response literature makes the trade visible, reporting mean nadir concentrations across five weekly injection doses of 253, 306, 542, 1,345 and 2,370 ng/dL.[3] The existence of a reported nadir is the point — with interval dosing, there is a low point, and the dose determines where it sits.
That thread continues in daily vs weekly dosing.
Where skin came in
The other escape route was transdermal. Skin absorption bypasses first-pass hepatic metabolism, and it allows daily administration rather than interval dosing.
It brings its own constraint, and it is not a small one: a treated skin surface can transfer drug to someone else. Testosterone gels carry an FDA boxed warning for secondary exposure, with virilization reported in children exposed through contact — most cases regressing on removal, but in a few, enlarged genitalia not fully returning to age-appropriate size and bone age remaining modestly advanced.[4] See gel transfer risk.
No delivery route is free. Each solves the liver problem and introduces something else.
Frequently asked questions
Why can't I just take a testosterone pill? Because oral testosterone is inactivated in the liver.[1] Modified oral androgens that survive first-pass metabolism exist but carry hepatic toxicity concerns and are not the basis of standard replacement therapy.
Is injection better than a topical? The guideline does not rank them. It asks clinicians to weigh pharmacokinetics, patient preference, formulation-specific adverse effects, treatment burden and cost together.[2]
Has the delivery problem been solved? Sufficiently that physiological serum levels can now be achieved — after 85 years of incremental improvement.[1]
Where the story goes next
The liver problem produced the injectable era first: propionate every few days, then enanthate for fifty years, then the long-acting undecanoate — each trading frequency against stability, and each with its own failure mode. Those seasons of The T Files are in progress.
In the meantime: how long TRT takes to work and the published clinical evidence on transdermal spray delivery.
References
4 sources
- Nieschlag E, Nieschlag S. ENDOCRINE HISTORY: The history of discovery, synthesis and development of testosterone for clinical use. Eur J Endocrinol. 2019;180(6):R201–R212. doi:10.1530/EJE-19-0071 · PMID 30959485
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
- Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–E1181. doi:10.1152/ajpendo.2001.281.6.E1172 · PMID 11701431
- U.S. Food and Drug Administration. AndroGel (testosterone gel) 1% — prescribing information, including BOXED WARNING: secondary exposure to testosterone. Reference ID 021015s044. 2019. accessdata.fda.gov
Practical questions about membership, labs and using the spray are answered in the Learn Hub FAQ.